Site Sponsors
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Strem Chemicals - Nanomaterials for R&D
  • Park Systems - Manufacturer of a complete range of AFM solutions
Posted in | Nanomedicine | Nanobusiness

There is 1 related live offer.

Save 25% on magneTherm

pSivida Signs Evaluation Agreement for Nanotechnology Related Cardiovascular Drug Delivery

Published on June 29, 2007 at 4:20 PM

Global drug delivery company, pSivida Limited announced that it has entered into an evaluation agreement with an undisclosed large global medical device company to evaluate cardiovascular delivery of drugs using pSivida’s drug delivery technologies.

pSivida is a global bio-nanotech company committed to the biomedical sector and the development of drug delivery products.

pSivida owns the rights to develop and commercialize a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon™, which has applications in drug delivery, wound healing, orthopedics, and tissue engineering. The most advanced BioSilicon™ product, BrachySil™ delivers a therapeutic, P32 directly to solid tumors and is presently in Phase II clinical trials for the treatment of pancreatic cancer.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit